Introduction/Background Most high-grade ovarian carcinomas (HGOCs) are sensitive to carboplatin (CBP)-based chemotherapy but frequently recur within 24 months. CT45 genes show oncogenic function. Coscia et al. (2018) studied CT45 as a significant marker of a positive response to chemotherapy. The aim of the study was to establish the relevance of CT45 gene expression as a predictive biomarker in the recurrence of Ovarian Cancer

Methodology Intra-operative tumor tissues (in RNA later) were collected from all the cases of ovarian tumors (N = 45) being operated on for malignancy and stored at -80 °C. All the cases reported as HGSC confirmed by histopathology (N = 39) were selected for further study. Upfront surgery cases (group A) were 26/39 (66.6%), and NACT (3#) (group B) cases were 13/39 (33.3%). These tissue samples were subjected to RNA isolation and cDNA gene expression through real-time qPCR. The median (0.16) of fold change was set as cut off. CT45-expression was correlated with the recurrence of ovarian cancer.

Results In Group A (n = 26), high and low expression were seen in 50% of cases (n = 13) each. Recurrence was seen in 9/26 (34.6%) cases, with 7/9 (77.7%) cases having low CT45 expression. None of the cases with high CT45 expression showed a recurrence.

In Group B (n = 13), 6 (46%) and 7 (53%) cases showed high and low gene expression, respectively. Recurrence was seen in 3/7 (43%) cases with low CT45 expression. In the remaining cases, recurrence could not be established yet. No case with high CT45 expression showed a recurrence.

Conclusion This study shows high CT45 expression is associated with a low recurrence rate and a better prognosis. Possibly this is the first pilot study to see the relevance of CT45 as a prognostic biomarker in OC.

Disclosures I declare that there is no COI related to this abstract.